EP 1638603 A1 20060329 - METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES CAUSED BY AN INFLAMMATORY RESPONSE MEDIATED BY ENDOGENOUS SUBSTANCE P BY USING ANTI-SUBSTANCE P ANTIBODIES
Title (en)
METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES CAUSED BY AN INFLAMMATORY RESPONSE MEDIATED BY ENDOGENOUS SUBSTANCE P BY USING ANTI-SUBSTANCE P ANTIBODIES
Title (de)
VERFAHREN ZUR VORBEUGUNG UND BEHANDLUNG VON KRANKHEITEN VERURSACHT DURCH EINEN DURCH ENDOGENE SUBSTANZ-P MEDIIERTEN ENTZÜNDUNGSRESPONS UNTER VERWENDUNG VON ANTIKÖRPERN GEGEN SUBSTANZ-P
Title (fr)
PROCEDES DE PREVENTION ET DE TRAITEMENT DE MALADIES DUES A UNE REPONSE INFLAMMATOIRE INDUITE PAR LA SUBSTANCE P ENDOGENE, PAR L'UTILISATION D'ANTICORPS ANTI-SUBSTANCE P
Publication
Application
Priority
- US 0001032 W 20000114
- US 11683599 P 19990122
Abstract (en)
[origin: WO0043040A1] The present invention provides methods for preventing or treating a disease in a subject which is caused by an inflammatory response to a disease or syndrome which is mediated by endogenous substance P. These methods comprise the administration to the subject of a pharmaceutically-effective amount of anti-substance P antibodies, or anti-substance P antibody fragments, such as F(ab)2 fragments, thereby inhibiting the activity of endogenous substance P in the subject. By inhititing the activity of endogenous substance P in the subject, the levels of cytokines produced by T lymphocytes present in the subject are reduced, the signals which direct the inflammatory response to the infection become altered, and the amount of cytokine-induced inflammation becomes reduced. Respiratory syncytial virus is one example of an agent which causes an infection which often results in a disease caused by an inflammatory response to the infection mediated by endogenous substance P. Generally, from about 0.001 mg to about 10 g of anti-substance P antibodies, or anti-substance P antibody fragments, per kilogram of body weight per day are administered to a mammalian subject, with from about 1 mg to about 1000 mg of anti-substance P antibodies, or anti-substance P antibody fragments, per kilogram of body weight per day being preferred.
IPC 1-7
A61K 39/395; A61P 1/00; A61P 11/00; A61P 19/00; A61P 31/00; A61P 37/00; C07K 7/22
IPC 8 full level
A61K 39/395 (2006.01); A61P 1/00 (2006.01); A61P 11/00 (2006.01); A61P 19/00 (2006.01); A61P 29/00 (2006.01); A61P 31/00 (2006.01); A61P 37/00 (2006.01); C07K 16/18 (2006.01); C07K 16/26 (2006.01)
CPC (source: EP)
A61P 1/00 (2017.12); A61P 11/00 (2017.12); A61P 19/00 (2017.12); A61P 29/00 (2017.12); A61P 31/00 (2017.12); A61P 37/00 (2017.12); C07K 16/26 (2013.01); A61K 2039/505 (2013.01); C07K 2317/54 (2013.01)
Citation (search report)
See references of WO 0043040A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0043040 A1 20000727; AU 2414600 A 20000807; AU 770737 B2 20040304; CA 2359776 A1 20000727; CA 2359776 C 20100803; EP 1638603 A1 20060329
DOCDB simple family (application)
US 0001032 W 20000114; AU 2414600 A 20000114; CA 2359776 A 20000114; EP 00902427 A 20000114